Z. Yu

A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma.

J. Zeldis, J. Bladé, S. Rajkumar, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older.

A. Palumbo, R. Hájek, M. Delforge, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1 study of tazarotene in adults with advanced cancer

A. Harris, T. Ganesan, G. Rustin, 2003, British Journal of Cancer.

Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin.

J. Zeldis, D. Weber, R. Knight, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, J. Zeldis, M. Petrucci, 2009, Leukemia.

Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009).

A. Belch, J. Zeldis, D. Weber, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy or adjuvant chemotherapy is similarly beneficial for locally advanced gastric cancer patient

Z. Zhu, C. Li, J. Li, 2023, medRxiv.

Long-term safety of lenalidomide (LEN) in relapsed/refractory multiple myeloma (RRMM) patients (Pts): Analysis of pooled data.

G. Morgan, S. Lonial, R. Orlowski, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.